HistoSonics Explores Strategic Sale Amid $2.5B+ Interest from Medtronic, GE Healthcare, and Johnson & Johnson

According to the Financial Times, HistoSonics is considering a potential sale after receiving multiple acquisition offers. The current marketHistoSonics Valued at Over $2.5 Billion. Medtronic, GE, and Johnson & Johnson Among Healthcare Giants in Acquisition Talks, Sources SayHistoSonics。

In传出HistoSonics is willing to sell before,HistoSonics has beenExplored the IPO path,But due to the impact of current capital market volatility on the listing process, selling was ultimately prioritized.

CurrentlyCiti Bank Served asHistoSonics' Financial Advisor,Citi Bank Is Actively Seeking Strong Buyers. In the coming weeks, more buyers will participate in the bidding, and giants such as Boston Scientific and Siemens will also make offers.

Among them, Johnson & Johnson is the most promising final buyer. Last year, Johnson & Johnson had already proceeded through its subsidiary.Venture Capital Firm JJDCParticipated in HistoSonics' Series D financing (USD 102 million).

Johnson & Johnson had previously participated in HistoSonics' $102 million Series D financing last year through its venture capital arm JJDC, demonstrating its interest inStrong interest in HistoSonics technology. Oncology has always been one of Johnson & Johnson's key focus areas, and it plays a significant role in its surgical business (Ethicon).Mostly related to tumorsFor example, microwave ablation products (acquired NeuWave for $55 million in 2016), soft tissue surgical robots (acquired for $3.4 billion)Auris Health), ultrasonic scalpel, stapler, etc. These products can all be used withHistoSonics' Non-Invasive Ultrasound Ablation Tumor RobotEdison forms a perfect complement.

Despite Johnson & Johnson's promising prospects, in this commercialized market, the final decision still depends on the bid (no one would turn down money).

The reason why HistoSonics is favored by giants and they are willing to spend huge sums to acquire it isThe revolutionary development by HistoSonicsNon-invasive Ultrasound Ablation Tumor RobotEdison's Excellent Efficacy.

According to recentHistoSonics AnnouncesThe 12-month follow-up data from the prospective clinical study (HOPE4LIVER) showedEdison's Excellent Clinical Outcomes.

Specific Research Data

• The achievement rate of the primary efficacy endpoint was 95.5% (42/44 tumors completely ablated).

• Primary safety endpoint achieved, with only 6.8% (3/44) of patients experiencing major complications.

• Only 1 case of non-serious device-related adverse event occurred 30 days later, and it resolved on its own.

• 19 cases were HCC patients, and 28 cases were metastatic tumors (39.3% originating from colorectal cancer). The 12-month local tumor control rate reached 90%, surpassing current standard local therapies.

Clinical data reveals the significant market potential of Edison. It not only enables precise ablation of lesions but also allows doctors to monitor the treatment process through a real-time visualization system, with recovery speed in the treated area notably superior to traditional therapies.

CurrentlyEdison has received FDA approval,Becoming the first and only approved treatment for liver tumors in the United StatesNon-invasive Ultrasound Ablation Tumor Robot. Besides liver cancer,HistoSonics is also actively advancingEdison inApplication in the fields of kidney cancer and pancreatic cancer.

As a disruptive technology, no matter who obtainsHistoSonics will reshape the market landscape of minimally invasive tumor treatment.

Edison

EdisonIt is a sophisticated energy platform, comprising a robotic arm, an ultrasound probe, an imaging display, and a control panel, with an integrated microcomputer responsible for image processing and controlling the movement of the robotic arm. It can deliver pulsed acoustic wave energy into the human body without any incisions or needles and is capable of disrupting tissue at the subcellular level, while doctors can monitor the "bubble cloud" and treatment efficacy in real time through the device’s display.

EdisonAble to provide patients with precise, controllable, personalized, and tissue-specific treatments.

Tissue fission uses pulsed sound waves to induce "bubble clouds" from naturally occurring gases within the target tissue. These bubble clouds form and collapse within microseconds, generating mechanical forces sufficient to disrupt tissue at cellular and subcellular levels in a non-invasive and non-thermal manner.